Truist raises Amgen stock price target on earnings beat

Amgen’s Q3 2026 results beat expectations, with adjusted EPS of $6.45 versus $5.76 forecast and revenue of $10.4B versus $10.06B; the company raised full-year revenue guidance to $38.9B–$39.7B and EPS guidance to $22.90–$23.70. Truist raised its price target to $398 from $380 but maintained Hold, noting that key pipeline drivers—including dazodalibep data and MariTide’s 2027 phase III readouts—still require validation. The shares were reported at $461.26, near their 52-week high, after gaining 60% over the past year.

Analysis

The setup is less about whether Amgen can beat near-term estimates and more about how much of that execution is already priced in. Shares sit above every cited analyst target ($398–$460), so another estimate upgrade may have limited marginal impact unless it expands confidence in the pipeline or lifts medium-term earnings power. The downside is a multiple reset if upcoming Sjögren’s data disappoint or if MariTide’s Phase III profile fails to support a credible obesity strategy; neither asset is yet validated by the evidence described here.

Near term (days to 1–3 months), raised guidance and product momentum should support sentiment, but ACR data are the clearest catalyst for changing the pipeline debate. Over 6–18 months, the key question is whether pipeline potential converts into durable growth without the operating-margin pressure the company has sought to avoid. The contrarian risk is that investors overvalue near-term commercial execution while treating 2027 readouts as optionality; at this share price, that optionality may already be expensive. Conversely, strong data could make current analyst targets stale, so the price-target gap alone is not a short thesis.

Key Decisions for Investors

• Do not chase AMGN at the reported $461 level. For existing holders, consider trimming a portion into strength and retain exposure only where the position thesis depends on confirmed commercial execution rather than unvalidated pipeline value.
• Treat ACR/OASIZ data as the next decision point: add only if the full data materially strengthen the efficacy, safety, or competitive case for dazodalibep; reduce risk on ambiguous or weaker-than-expected results. Verify the release timing and full dataset before positioning.
• For downside protection rather than an outright short, evaluate a defined-risk AMGN put spread around the data catalyst only after checking option-implied volatility, liquidity, and event pricing; elevated implied volatility could make protection unattractive.
• Falsifiers: sustained share strength accompanied by further upward revisions to full-year guidance, or compelling OASIZ data, would weaken the trim/hedge thesis. A guidance reduction, deterioration in key-product momentum, or data that narrow dazodalibep’s addressable opportunity would strengthen it.